In a recent study, humanized anti-NS1 monoclonal antibodies (mAbs) were generated and tested on mice infected with all four serotypes of DENV (1). The results were promising, showing the efficacy of the humanized mAbs in inhibiting NS1-induced hyperpermeability and triggering Fcγ-dependent complement-mediated cytolysis. This inhibition activity was further demonstrated by an antibody-dependent cellular cytotoxicity (ADCC) assay. With no cure currently available, these findings suggest the potential of humanized anti-NS1 mAbs as a therapeutic agent for DENV infection.
Leadgene proudly contributed to this study by providing the key reagent, humanized anti-NS1 mAb 2E8 and 33D2 clones, and performing the ADCC assay.
Our collection of antibodies and antigens of DENV offer a new opportunity for further advancements in the study of DENV infection.
For the product details click here.
|
|
|
|
References:
